Having trained in Cambridge, then Oxford, as a clinician-scientist (PhD FRCP), Damian practiced clinical neurology in Nottingham and Cambridge before leading a basic neuroscience research group at the University of Cambridge for 10 years.
He completed the Golden Triangle with an honorary appointment at UCL.
Since leaving academia he has gained commercial and entrepreneurial experience as a head of early drug discovery at AstraZeneca Neuroscience and co-founder of the HealthTech startup GPnotebook.
Prior to joining CIC, Damian was EiR at Oxford Science Enterprises, where he championed and built neuroscience biotechs, including EndLyz Inc, focused on Parkinson’s disease therapies, and Human Centric Drug Discovery, which has a platform approach to pain and Parkinson’s disease drug discovery.
At CIC, Damian is building a therapeutics start-up using Cambridge technology to combat diseases such as Alzheimer’s and Huntington’s.